07.29.26 -- Full FDA Approval For TECELRA Is More Than A Regulatory Win For Solid Tumors

Build audit readiness into your facility design from day one. Discover how early cross-functional engagement and early contamination control planning prevent costly startup delays and rework.

See how a leading genomics facility advances long‑read sequencing through rigorous QC and flexible workflows, offering practical insights for researchers aiming to improve sequencing outcomes.

Look beyond brochure specifications for hazardous compounding. Learn the essential airflow, structural, and pressure requirements needed to ensure long-term facility safety.

Transitioning platforms requires strong regulatory planning. Examine how analytical comparability, structured risk assessments, and bridging strategies help support a smooth, compliant shift.

A clear shift is reshaping life science operations. Understand how integrating data streams across the product lifecycle strengthens predictive compliance and sharpens operational focus.

Bringing gene editing therapies to market involves navigating complex global rules. Strategic planning, early risk assessment, and manufacturing alignment can significantly streamline work.

Rising Annex 1 demands are pushing facilities to rethink contamination control. See how RABS retrofits offer a practical path to compliance, combining effective containment and faster implementation.

Single-use technology suppliers must align with advanced therapy manufacturers to de-risk manufacturing processes and chemical composition requirements to maintain the safety and efficacy of new treatments.

Explore how next-gen technologies, from mRNA platforms to digital tools, are transforming vaccine manufacturing to make it more sustainable, flexible, and accessible.

Scaling mammalian platforms requires downstream precision and viral safety. Review practical methods to lower scale-up risk, enhance analytics, and maintain a steady, compliant drug supply.

Proper material transfer requires detailed operational focus. Evaluate packaging integrity, ensure complete disinfection coverage, and manage time-sensitive items with exact precision.

Staying aligned with shifting Annex 1 expectations is essential for sterile drug manufacturing. Review draft USP guidance to strengthen sterility assurance and maintain regulatory alignment.